8-K: Bausch Health Secures Agreements with Key Directors to Prevent Proxy Contests and Ensure Board Stability

Bausch Health Companies Inc. has entered into letter agreements with Carl Icahn, John Paulson, and Sarah Kavanagh to prevent proxy contests and ensure their support for management nominees on the Bausch + Lomb Corporation board.

Summary

• Bausch Health Companies Inc. (BHCI) has entered into letter agreements with Carl Icahn (and the Icahn Group), John Paulson (and the Paulson Group), and Sarah Kavanagh (and the Kavanagh Group).
• These agreements aim to prevent the directors from engaging in actions that could destabilize the company, such as proxy contests.
• If any of these directors engage in a 'Specified Action,' they must immediately resign from both the BHCI Board and the Bausch + Lomb Corporation (B+L) Board.
• As long as they haven't engaged in a 'Specified Action,' BHCI will support their nomination to the B+L Board and vote in their favor.
• The BHCI Board will also offer them the opportunity to be members of any newly-created committees (unless there are conflicts of interest).
• 'Specified Actions' include instigating proxy contests, presenting proposals at shareholder meetings, soliciting proxies, seeking to nominate directors in opposition to the company's recommendations, or acquiring more than 19.99% of BHCI's common shares.
• The agreements are governed by Delaware law and can be enforced through injunctions.

Sentiment

Score: 7

Explanation: The document reflects a proactive approach to corporate governance and board stability, which is generally viewed positively by investors. However, there are potential concerns about limiting director independence, which tempers the overall sentiment.

Positives

• The agreements aim to prevent disruptive actions like proxy contests, promoting board stability.
• BHCI's commitment to support the directors' nomination to the B+L board fosters a collaborative environment.
• The agreements provide a clear framework for director conduct, reducing uncertainty and potential conflicts.
• The agreements are governed by Delaware law, providing a well-established legal framework for enforcement.

Negatives

• The agreements could be seen as limiting the directors' ability to act independently and represent shareholder interests.
• The definition of 'Specified Actions' might be interpreted broadly, potentially restricting legitimate director activities.
• The agreements could create a perception of entrenchment, making it harder for dissenting voices to be heard on the board.

Risks

• A director might inadvertently trigger the resignation clause by engaging in an action that is later deemed a 'Specified Action'.
• The agreements could be challenged in court by shareholders who believe they unduly restrict director independence.
• Changes in control of BHCI could lead to disputes over the interpretation or enforcement of the agreements.

Future Outlook

The agreements are intended to ensure board stability and support for management nominees on the B+L board, which could positively influence the future direction of both Bausch Health and Bausch + Lomb.

Industry Context

These agreements are not uncommon in situations where activist investors or significant shareholders have board representation, as they aim to balance the need for independent oversight with the desire to avoid disruptive proxy contests.

Comparison to Industry Standards

• Similar agreements are often seen when companies have significant shareholders with board representation, such as ValueAct at Citigroup or Pershing Square at Chipotle.
• These agreements typically include standstill provisions, voting agreements, and limitations on acquiring additional shares.
• The 19.99% ownership threshold is a common trigger for restrictions in these types of agreements, as it's just below the level that would trigger a mandatory tender offer in many jurisdictions.

Stakeholder Impact

• Shareholders may benefit from the increased board stability and reduced risk of proxy contests.
• Employees may experience a more stable work environment due to the reduced risk of corporate disruption.
• The agreements could impact the company's ability to respond to changing market conditions if director independence is unduly restricted.

Next Steps

• The directors are expected to adhere to the terms of the letter agreements.
• BHCI will support the directors' nomination to the B+L board.
• The BHCI Board will offer the directors the opportunity to be members of any newly-created committees.

Key Dates

Keywords

Bausch Health, Icahn, Paulson, Kavanagh, Proxy Contest, Board of Directors, Bausch + Lomb, Director Nomination, Corporate Governance, Shareholder Agreement